Denali_T_Logo_02.jpg
Denali Therapeutics Announces New Interim Data from Phase 1/2 Study of DNL310 (ETV:IDS) in MPS II (Hunter Syndrome) at SSIEM 2022
August 31, 2022 08:00 ET | Denali Therapeutics Inc.
Additional one-year data continue to show rapid and sustained normalization to healthy levels of CSF heparan sulfate and improvements in biomarkers of lysosomal function consistent with durable...
Denali_T_Logo_02.jpg
Denali Therapeutics Reports Second Quarter 2022 Financial Results and Business Highlights
August 08, 2022 16:01 ET | Denali Therapeutics Inc.
SOUTH SAN FRANCISCO, Calif., Aug. 08, 2022 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (Nasdaq: DNLI), a biopharmaceutical company developing a broad portfolio of product candidates engineered to...
Denali_T_Logo_02.jpg
Denali Therapeutics and Biogen Announce Initiation of Phase 2b Study of LRRK2 Inhibitor in Parkinson’s Disease
May 31, 2022 08:00 ET | Denali Therapeutics Inc.
BIIB122 is an inhibitor of LRRK2, a potential novel target intended to impact the underlying biology and slow the progression of Parkinson’s diseasePhase 2b LUMA to enroll approximately 640...
Denali_T_Logo_02.jpg
Denali Therapeutics Reports First Quarter 2022 Financial Results and Business Highlights
May 05, 2022 16:01 ET | Denali Therapeutics Inc.
SOUTH SAN FRANCISCO, Calif., May 05, 2022 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (Nasdaq: DNLI), a biopharmaceutical company developing a broad portfolio of product candidates engineered to...
Denali_T_Logo_02.jpg
Denali Therapeutics Announces Achievement of RIPK1 Milestone for Phase 2 Clinical Trial Initiation in ALS by Sanofi
May 02, 2022 08:30 ET | Denali Therapeutics Inc.
Partner Sanofi has commenced dosing in a Phase 2 clinical trial of SAR443820 (DNL788) in individuals with amyotrophic lateral sclerosis (ALS)Denali to receive a milestone payment of $40 million from...
Denali_T_Logo_02.jpg
Denali Therapeutics Appoints Alexander Schuth as Chief Operating and Financial Officer as Steve Krognes Transitions to Denali Board of Directors
March 15, 2022 16:30 ET | Denali Therapeutics Inc.
SOUTH SAN FRANCISCO, Calif., March 15, 2022 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (NASDAQ: DNLI), a biopharmaceutical company developing a broad portfolio of product candidates engineered to...
Denali_T_Logo_02.jpg
Denali Therapeutics Announces Initiation of Phase 1/2 Clinical Trial of DNL593 (PTV:PGRN) for Frontotemporal Dementia-Granulin (FTD-GRN)
March 09, 2022 08:00 ET | Denali Therapeutics Inc.
SOUTH SAN FRANCISCO, Calif., March 09, 2022 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (NASDAQ: DNLI), a biopharmaceutical company developing a broad portfolio of product candidates engineered to...
Denali_T_Logo_02.jpg
Denali Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Business Highlights
February 28, 2022 16:01 ET | Denali Therapeutics Inc.
SOUTH SAN FRANCISCO, Calif., Feb. 28, 2022 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (NASDAQ: DNLI), a biopharmaceutical company developing a broad portfolio of product candidates engineered to...
Denali_T_Logo_02.jpg
Denali Therapeutics Announces Continued Progress in DNL310 (ETV:IDS) Program for MPS II (Hunter Syndrome) Supporting Planned Initiation of Phase 2/3 Clinical Trial
February 10, 2022 08:00 ET | Denali Therapeutics Inc.
Longer-term data in 20 patients show sustained normalization to healthy levels of CSF heparan sulfate and improvements in markers of lysosomal function consistent with durable CNS activity, now with...
Denali_T_Logo_02.jpg
Denali Therapeutics Announces Appointment of Erik Harris to Board of Directors
February 07, 2022 09:00 ET | Denali Therapeutics Inc.
SOUTH SAN FRANCISCO, Calif., Feb. 07, 2022 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (NASDAQ: DNLI), a biopharmaceutical company developing a broad portfolio of product candidates engineered to...